Investor dapat menerima bukti bantuan kecerdasan buatan dalam penemuan obat pada paruh kedua
trial for SGR-2921, which targets KRAS mutant tumors, is expected to be completed by the end of this year. Schrodinger\’s stock has had a volatile year, currently down 18%, but analysts are bullish on its long-term prospects. Goldman Sachs analyst Graig Suvannavejh wrote in a note in June that he expects Schrodinger to start to … Baca Selengkapnya